Fostering a rich, supportive, and diverse community in which to study is high on the school’s agenda. Informal fall and winter gatherings promoted and encouraged fellowship among students.
On Feburary 6, teams of Gerstner Sloan-Kettering students and faculty joined 2,500 indoor cyclists from New York and Chicago to raise more than $2.4 million to support rare cancer research at Memorial Sloan-Kettering Cancer Center.
Cancer biologist Andrea Ventura is the incumbent of a Geoffrey Beene Junior Faculty Chair at the Sloan-Kettering Institute, he devotes his research to the nascent field of microRNA expression, seeking to understand how these small RNAs act on genes to promote or suppress cancer.
Hedvig Hricak, Chair of Memorial Sloan-Kettering’s Department of Radiology and incumbent of the Carroll and Milton Petrie Chair, has been named the 95th President of the Radiological Society of North America Board of Directors.
Each year since 2007, Memorial Sloan-Kettering’s postdoctoral researchers have had the opportunity to showcase their research accomplishments at the annual Postdoctoral Research Symposium.
A multidisciplinary team of Memorial Sloan-Kettering investigators has shown for the first time that the gene that causes the inherited form of Parkinson’s disease also plays a role in many types of cancer, including colon and lung cancers and glioblastoma, the most common form of brain cancer.
In October 2009, a team of eight researchers, six of whom are at Memorial Sloan-Kettering, received an $11 million, five-year grant from the NCI to form one of 12 Physical Sciences-Oncology Centers (PS-OCs) in the United States.
Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan-Kettering Cancer Center shows that circulating tumor cells - cancer cells that break away from a primary tumor and disseminate to other areas of the body - can also return to and grow in their tumor of origin, a newly discovered process called “self-seeding.”
Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.
